SG Americas Securities LLC Increases Position in Soleno Therapeutics, Inc. $SLNO

Key Points

• Institutional buying: SG Americas Securities raised its stake by 171.9% to 40,198 shares (~$1.86M) and multiple large funds (Wellington, Invesco, Franklin, others) materially increased positions, leaving institutional ownership at 97.42%.
• Securities class action risk: A class action has been filed over alleged misstatements about the DCCR (VYKAT™ XR) program and multiple plaintiff firms are soliciting lead plaintiffs, keeping litigation in the news and raising potential financial and reputational exposure.
• Mixed fundamentals: Soleno beat quarterly estimates (EPS $0.80 vs $0.64; revenue $91.7M vs $88.6M) but analysts still forecast a -3.72 EPS for the year and the stock trades at a high P/E (~171.7) with a $2.04B market cap.

SG Americas Securities LLC increased its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 171.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 40,198 shares of the company's stock after purchasing an additional 25,412 shares during the quarter. SG Americas Securities LLC owned 0.07% of Soleno Therapeutics worth $1,861,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of SLNO. Wellington Management Group LLP increased its position in shares of Soleno Therapeutics by 272.3% in the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company's stock valued at $156,298,000 after buying an additional 1,691,057 shares in the last quarter. Braidwell LP purchased a new position in Soleno Therapeutics in the 3rd quarter valued at about $86,662,000. Invesco Ltd. lifted its position in shares of Soleno Therapeutics by 132.3% in the third quarter. Invesco Ltd. now owns 1,500,525 shares of the company's stock valued at $101,435,000 after acquiring an additional 854,551 shares in the last quarter. Commodore Capital LP lifted its holdings in Soleno Therapeutics by 121.3% in the 3rd quarter. Commodore Capital LP now owns 1,350,000 shares of the company's stock valued at $91,260,000 after purchasing an additional 740,000 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Soleno Therapeutics by 348.4% in the third quarter. Franklin Resources Inc. now owns 835,751 shares of the company's stock worth $56,497,000 after buying an additional 649,349 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company's stock.

Soleno Therapeutics Price Performance

SLNO opened at $39.49 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80. Soleno Therapeutics, Inc. has a one year low of $29.43 and a one year high of $90.32. The business's 50-day simple moving average is $37.80 and its 200-day simple moving average is $47.85. The stock has a market capitalization of $2.04 billion, a P/E ratio of 171.70 and a beta of -2.81.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Unusually high options volume and elevated trading activity in SLNO, indicating increased speculation and short‑term volatility rather than a definitive directional signal. Soleno Therapeutics Sees Unusually High Options Volume NASDAQ: SLNO
• Negative Sentiment: A securities class action has been filed alleging material misstatements/omissions regarding Soleno’s Phase 3 program for DCCR (VYKAT™ XR); the complaint follows the company’s November 5, 2025 update on the drug and seeks to represent investors who bought between March 26 and November 4, 2025. Litigation filing increases potential financial liability and management distraction. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman
• Negative Sentiment: Multiple plaintiff firms (Schall, Faruqi & Faruqi, Pomerantz, Rosen, Kirby McInerney, Howard G. Law Offices and others) are actively soliciting lead plaintiffs and reminding investors of the May 5, 2026 deadline — increasing the likelihood of consolidated litigation and media coverage. These coordinated solicitations signal ongoing legal pressure and potential settlement exposure. SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm Faruqi & Faruqi Deadline Reminder Howard G. Law Offices Solicitation
• Negative Sentiment: Widespread press outreach by plaintiff firms (Pomerantz, Rosen, Hagens Berman, Kirby McInerney, etc.) is keeping the litigation story in the news cycle and may suppress sentiment until the legal exposure is resolved or clarified. Class Action Deadline PR Rosen Reminder
• Negative Sentiment: Media coverage notes subdued investor sentiment and growth concerns tied to the DCCR launch issues; continued uncertainty around commercial performance and clinical program messaging can pressure valuation multiple and investor confidence. Investor Sentiment Subdued Amid Growth Concerns

Analysts Set New Price Targets

A number of research firms have weighed in on SLNO. Wells Fargo & Company lowered their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an "overweight" rating on the stock in a research note on Friday, February 27th. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a report on Tuesday, January 13th. Zacks Research downgraded shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 3rd. Oppenheimer dropped their target price on Soleno Therapeutics from $110.00 to $80.00 and set an "outperform" rating for the company in a research report on Wednesday, March 18th. Finally, Wall Street Zen downgraded shares of Soleno Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday, March 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $102.00.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

Want to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.